Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Definitive Chemoradiotherapy on Respiratory Function Tests and Quality of Life Scores During Treatment of Lung Cancer

  • Duman, Evrim (Department of Radiation Oncology, Antalya Education and Research Hospital) ;
  • Yildirim, Mustafa (Ministry of Health Batman Regional Goverment Hospital, Department of Medical Oncology) ;
  • Kaya, Vildan (Suleyman Demirel University, Department of Radiation Oncology) ;
  • Ozturk, Duriye (Department of Radiation Oncology, Afyon Kocatepe University) ;
  • Inal, Aysun (Department of Radiation Oncology, Antalya Education and Research Hospital) ;
  • Akarsu, Zeynep (Department of Radiation Oncology, Antalya Education and Research Hospital) ;
  • Gunduz, Seyda (Department of Medical Oncology, Antalya Education and Research Hospital) ;
  • Yildiz, Mustafa (Department of Medical Oncology, Antalya Education and Research Hospital)
  • Published : 2015.10.06
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Chemoradiotherapy is an important treatment modality for lung cancers. The aim of this study was to investigate alterations in, as well as the interrelationship between, lung function and quality of life of patients receiving chemoradiotherapy due to locally advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) limited to the thorax. Materials and Methods: The study included patients receiving definitive chemoradiotherapy for lung carcinoma. The respiratory function of the patients was assessed by measuring forced expiratory volume in 1 s per unit (FEV1) and forced expiratory volume in 1s per unit of vital capacity (FEV1/VC) before, in the middle of and after treatment. During the study, EORTC QLQ C30 and LC13 questionnaires developed by the Committee of the European Organization for Research and Treatment of Cancer (EORTC) were employed to evaluate the quality of life on the same day as respiratory function tests (RFT). Findings: The study included 23 patients in total: 19 (82.6%) diagnosed with NSCLC and 4 (17.4%) with SCLC. The average percentage FEV1 was $55.6{\pm}21.8%$ in the pre-treatment period, $56.2{\pm}19.2%$ in the middle of treatment and $60.4{\pm}22%$ at the end of treatment. The improvement in functional scores, symptom scores and general health scores during treatment was not statistically significant (P= 0.568, P= 0.734, P= 0.680, P=0.757 respectively). Conclusions: Although this study showed an improvement in respiratory function and quality of life of patients during treatment with thoracic chemoradiotherapy, no statistically significant results were obtained. While evaluating the effectiveness of treatments for lung carcinoma, the effects of treatment on respiratory function and quality of life should be considered.

Keywords

References

  1. Amoori N, Mirzaei, Cheraghi M (2014). Incidence of Cancers in Kuzestan Province of Iran: Trend from 2004 to 2008. Asian Pac J Cancer Prev, 15, 8345-49. https://doi.org/10.7314/APJCP.2014.15.19.8345
  2. Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV (2005). Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term diseasefree survival. Int J Radiat Oncol Biol Phys, 62, 639-644. https://doi.org/10.1016/j.ijrobp.2004.11.029
  3. Chang-Claude J, Illig T, Wichmann HE, Bickeboller H, Risch A (2008). Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol Biomarkers Prev, 17, 1127-35. https://doi.org/10.1158/1055-9965.EPI-07-2840
  4. Dong J, Kislinger T, Jurisica I, Wigle DA (2009). Lung cancer: developmental networks gone awry? Cancer Biol Ther, 8, 312-8. https://doi.org/10.4161/cbt.8.4.7522
  5. Fan M, Marks LB, Hollis D, et al (2001). Relating radiation induced regional lung injury to changes in pulmonary function tests. Int J Radiat Oncol Biol Phys, 51, 311-7.
  6. Gopal R, Starkschall G, Cox JD, et al (2003). Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiation Oncol Biol Phys, 56, 114-120. https://doi.org/10.1016/S0360-3016(03)00077-4
  7. Goldstraw P (2012). The 7th edition of TNM for lung and pleural tumours. J Clin Anal Med, 3, 123-7. https://doi.org/10.4328/JCAM.530
  8. Ha IB, Jeong BK, Jeong H, et al (2013). Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer. Radiat Oncol J, 31, 185-90. https://doi.org/10.3857/roj.2013.31.4.185
  9. Langendijk JA, Aaronson NK, de Jong JM, et al (2001). Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung, J Clin Oncol, 19, 2123-33.
  10. MacKinnon AC, Kopatz J, Sethi T (2010). The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. Br Med Bull, 95, 47-61. https://doi.org/10.1093/bmb/ldq023
  11. Marks LB, Fan M, Clough R, et al (2000). Radiation-induces pulmonary injury: symptomatic versus subclinical endpoints, Int J Radiation Biol 76, 469-475. https://doi.org/10.1080/095530000138466
  12. Mohan A, Singh P, Kubar S, et al (2008). Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 9, 557-62.
  13. Orley J, Kuyken W (1993). Quality of life assessment: international perspectives. proceedings of the jointmeeting organized by the who and the foundation IPSEN in Paris, s. 41-57.
  14. Ozturk A, Sarihan S, Ercan I, Karadag M (2009). Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy. Am J Clin Oncol, 32, 65-72. https://doi.org/10.1097/COC.0b013e31817e6ec2
  15. Panda R, Persai D, Mathur M, Sarlar BK (2013). Perception and practices of physicians in addressing the smokeless tobacco epidemic: findings from two states in India. Asian Pac J Cancer Prev, 14, 7237-42. https://doi.org/10.7314/APJCP.2013.14.12.7237
  16. Pijls-Johannesma M, Houben R, Boersma L, et al (2009). Highdose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiotherapy and Oncol, 91, 443-448 https://doi.org/10.1016/j.radonc.2009.02.010
  17. Rowell NP, O'Rourke NP (2004). Concurrent chemoradiotherapy in non-small-cell lung cancer. Cohrane Database Syst Rev, 18, 2140.
  18. Sauter W, Rosenberger A, Beckmann L, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  19. Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ (2001). Estimating the need for radiotherapy for lung cancer: An evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys, 49, 973-985. https://doi.org/10.1016/S0360-3016(00)01401-2
  20. Yuan S, Kirk A. Frey, et al (2012). Changes in global function and regional ventilation and perfusion on spect during the course of radiotherapy in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 82, 631-38. https://doi.org/10.1016/j.ijrobp.2011.07.044
  21. Wang LJ, Liu XJ, Guan Y, et al (2014). Optimal timing of radiotherapy with alternating/sequential radio-chemotherapy for limited-stage small cell lung cancer. Asian Pac J Cancer Prev, 15, 5697-99. https://doi.org/10.7314/APJCP.2014.15.14.5697